Automation in Biopharma Industry Global Market Report 2024

The automation in biopharma industry market size has grown strongly in recent years. It will grow from $1.94 billion in 2023 to $2.06 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth observed in the historical period can be ascribed to the heightened complexity in biopharmaceutical processes, a necessity for enhanced process efficiency, the expansion of biologics development and manufacturing, a growing demand for quality assurance and control, and the imperative to reduce time-to-market pressures.

The automation in biopharma industry market size is expected to see strong growth in the next few years. It will grow to $2.66 billion in 2028 at a compound annual growth rate (CAGR) of 6.6%. The anticipated growth in the forecast period can be linked to improvements in data integrity and documentation, the ascent of personalized medicine, the emergence of modular and flexible bioprocessing facilities, the evolution of automation platforms, a growing demand for biosimilars, and the adoption of smart sensors and the Internet of Things (IoT). Prominent trends expected in the forecast period encompass progress in robotics and automation technologies, advancements in single-use technologies, the integration of artificial intelligence in bioprocessing, developments in process analytical technologies (PAT), collaborative efforts between biopharma and technology companies, and an increased emphasis on sustainability in biopharma automation.

The growth of automation in the biopharma industry market is anticipated to be driven by the increasing integration of robots in pharmaceutical manufacturing. In this context, robots refer to sophisticated automated systems and machines employed in various tasks related to the production and packaging of pharmaceutical products. These robots find application in secondary packaging, intralogistics, laboratory automation, pick and place operations, automation of pharmacy processes, and personalized medicine within pharmaceutical manufacturing. Their utilization leads to heightened productivity, improved precision, reduced contamination risks, and enhanced worker safety. For instance, in Q3 2021, the North American robotics market witnessed significant growth, with 29,000 units ordered valued at $1.48 billion, marking a remarkable 37% increase in units sold. Notably, the life sciences, pharmaceutical, and biomedical sectors experienced a substantial 36% surge in the application of robotics during the first nine months of 2021. Consequently, the rising adoption of robots in pharmaceutical manufacturing is poised to propel the growth of automation in the biopharma industry market.

The growth of automation in the biopharma industry market is further expected to be fueled by the increasing pace of drug development. The process of drug development involves the discovery and introduction of new pharmaceutical products to the market. As drug development intensifies, the automation of processes becomes essential within the biopharma industry. Automated systems play a crucial role in streamlining processes, expediting research, ensuring precision, and enhancing overall efficiency. For example, in 2022, the Center for Drug Evaluation and Research (CDER) granted approval to 37 new drugs, categorized as novel drugs, with 54% of them receiving approval in the same year. Hence, the surge in drug development activities acts as a catalyst for the growth of automation in the biopharma industry market.

A prominent trend in the automation in the biopharma industry market is the adoption of technological advancements by major companies. These companies are actively engaged in developing advanced product technologies to fortify their positions in the market. An illustration of this trend is observed in the actions of PerkinElmer Inc., a US-based company providing scientific solutions and technologies. In September 2022, PerkinElmer Inc. introduced the Cellaca PLX Image Cytometry System, an advanced automated cell analysis solution designed to simplify cell and gene therapy research and manufacturing. This platform enables researchers to assess critical quality attributes of cell samples, including identity, quantity, and quality, through an automated workflow. The integrated system encompasses image cytometer hardware, software, validated consumables, and trackable data reporting, streamlining calibration and training requirements.

Major companies in the automation in biopharma industry market are actively developing advanced technologies, including automated customer data platforms (CDP)To cater to a larger customer base, boost sales, and increase revenue. An automated CDP is a software solution designed to automatically collect, organize, and analyze customer data from diverse sources in a centralized manner. For instance, Tealium, a US-based provider of customer data orchestration tools, launched Tealium for Pharma in July 2022. This verticalized platform is meticulously crafted to fully automate and enhance the customer experience for Pharma audiences, addressing the challenges posed by dynamic privacy and security regulations in the industry. Tealium's data-first offering integrates and automates data seamlessly, resulting in an elevated customer experience while adhering to the highest standards of Health Insurance Portability and Accountability Act (HIPAA) compliance.

In April 2022, Bruker Corporation, a US-based company specializing in scientific instruments for molecular and materials research, acquired Optimal Industrial Automation Limited for an undisclosed amount. This acquisition positions Bruker as a key provider of software and solutions for small molecule, biologic, and new drug modalities in pharma companies. Optimal Industrial Automation Limited, based in the UK, offers pharmaceutical and biopharmaceutical automation solutions, including process analytical technology (PAT), manufacturing automation, quality assurance (QA) software, and systems integration.

Major companies operating in the automation in biopharma industry market report are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Danaher Corporation, ABB Ltd, Siemens Healthineers AG, Emerson Electric Co., Becton Dickinson and Company (BD), Corning Incorporated, Rockwell Automation Inc., Agilent Technologies Inc., PerkinElmer Inc., Sartorius AG, bioMérieux SA, Mettler-Toledo International Inc., Beckman Coulter Inc., Waters Corporation, Pall Corporation, Bruker Corporation, Qiagen N.V., Eppendorf AG, Tecan Group Ltd., Promega Corporation, Brooks Automation Inc., Omron Automation, Hamilton Company, Integra Biosciences AG, Gilson Inc., Analytik Jena AG, BioTek Instruments Inc.

North America was the largest region in the automation in biopharma industry market in 2023. The regions covered in the automation in biopharma industry market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the automation in biopharma industry market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The principal technologies driving automation in the biopharma industry encompass automation technology and digitization technology. Automation technology encompasses the utilization of diverse technologies, such as robotics, artificial intelligence (AI), and software systems, to automate and streamline processes and tasks that were traditionally carried out by humans. This includes various components such as automation hardware, automation software, service project phases, and service operation phases, with applications spanning clinical phases, drug discovery phases, and production phases.

The automation in biopharma industry research report is one of a series of new reports that provides automation in biopharma industry market statistics, including the automation in biopharma industry's global market size, regional shares, competitors with a automation in biopharma industry market share, detailed automation in biopharma industry market segments, market trends and opportunities, and any further data you may need to thrive in the automation in biopharma industry. This automation in the biopharma industry market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The automation in biopharma industry market consists of revenues earned by entities by providing high-throughput screening, sample management, and cell culture automation used during the process. The market value includes the value of related goods sold by the service provider or included within the service offering. The automation in biopharma industry market also includes sales of automated dissolution testing systems, robotic sample storage and retrieval systems, and chromatography systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.